MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Key Developments

• In September 2023, Guardant Health, Inc., a precision oncology company, announced that Geisinger Health Plan offers coverage for the Guardant Reveal minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing.
• In April 2023, Sebia, a provider of clinical protein electrophoresis equipment and reagents, announced the launch of Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA) -licensed clinical laboratory and part of the Sebia Group.
• In December 2022, Adaptive Biotechnologies, a biotechnology company, announced the launch of its clonoSEQ Assay to detect minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL)
• In January 2021, GRAIL, Inc., a healthcare company, announced collaborations with Amgen Inc., a biopharmaceutical company, and AstraZeneca and Bristol Myers Squibb, to evaluate GRAIL Inc.’s methylation-based technology for the detection of minimal residual disease (MRD)